At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 12 enrolled

Drug / intervention

Pegylated interferon alfa-2adrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00078442

NCT00078442Phase 2Completed

Compare CT.gov

A Phase II Open-Label Pilot Trial of the Antiretroviral Activity, Safety, and Tolerability of Pegylated Interferon Alfa-2A (40KD) [PegasysTM] in HIV-1 Infected Subjects

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Feb 26, 2004·Updated Aug 7, 2009

In Brief

A Phase 2 clinical trial evaluating Pegylated interferon alfa-2a for HIV Infections. Completed, enrolled 12 participants across 3 sites.

Detailed Summary

Recombinant interferon (IFN) may be useful in the treatment of HIV. However, the high doses of IFN necessary to keep HIV under control limit its use due to toxic side effects. The purpose of this study is to test the safety and tolerability of weekly recombinant pegylated interferon (PEG-IFN) alfa-2a in HIV infected people who are currently on antiretroviral therapy (ART) interruption or who have not started taking anti-HIV drugs.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsHIV Infections

CountriesUnited States

Collaborators--

Timeline

Phase 2CompletedFinished

200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

First PostedFeb 2004

Enrollment StartMay 2006

Primary CompletionJan 2007

TodayJul 2026

First PostedFeb 26, 2004

Enrollment StartMay 1, 2006

Primary CompletionJan 1, 2007

TodayJul 2, 2026

Enrollment to primary: 8 monthsPosted 22.3 years ago

Interventions

Pegylated interferon alfa-2adrug

Recombinant PEG-IFN alfa-2a is a synthetic version of IFN and is used in hepatitis C virus treatment